Myriad Genetics (NASDAQ:MYGN) Rating Restated

New York: In a research note shared with investors and clients on Monday, 22 January, Barclays reiterated their Equal Weight rating on shares of Myriad Genetics (NASDAQ:MYGN). They currently have a $35.0 target price on the firm. Barclays’s target gives a potential downside of -9.37 % from the company’s current stock price.

NASDAQ:MYGN is currently trading 1.73% higher at $37.14 as of 6:04 AM New York time. Myriad Genetics’s stock is 0% over the last 200 days. It has underperformed the Standard & Poor’s 500 index, which has increased 6.00% over the same time.

According to data compiled by Thomson Reuters, Myriad Genetics (NASDAQ:MYGN)’s stock is covered by 12 equity analysts across the Street, with 3 analysts giving it a Sell rating, 8 a Buy rating, while 7 consider it a Hold. The 12-month consensus target price for the stock is $39.58, which reflects an upside potential of 6.57% over the current price.

Institutional Ownership

Tieton Capital Management Llc had the largest stake with ownership of 194,015 shares as of Q2 2015 for 3.43% of the stocks portfolio. North Tide Capital Llc is another quite bullish fund who is having 1.00M shares of Myriad Genetics or 2.24% of their stocks portfolio. Further, S&T Bank Pa have 2.2% of their stocks portfolio invested in the company for 644,837 shares. The New York-based fund Consonance Capital Management Lp disclosed it had purchased so far a stake worth about 1.68% of the fund’s stock portfolio in Myriad Genetics. The California-based fund Aimz Investment Advisors Llc is also positive about the stock, possessing 850,000 shares or 0.82% of their stocks portfolio.

Myriad Genetics (NASDAQ:MYGN) Profile

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other.

Myriad Genetics (NASDAQ:MYGN) traded up 1.73% on 22 January, hitting $37.14. A total of 824,172 shares of the company’s stock traded hands. This is down from average of 880,051 shares. Myriad Genetics has a 52 week low of $15.15 and a 52 week high of $37.23. The company has a market cap of $2.54 billion and a P/E ratio of 118.25.

Get the latest Myriad Genetics (NASDAQ:MYGN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Analysts at Barclays Kept the Same their Equal Weight rating for Myriad Genetics (NASDAQ:MYGN) with $35.0 PT appeared first on Octafinance.